Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Viking Therapeutics

Viking Therapeutics Unveils Monthly Weight-Loss Shot, Rocking Eli Lilly, Novo Nordisk

Viking Therapeutics stock rocketed Thursday after the company said it's exploring a monthly dose of its weight-loss drug.

Investors Business Daily

Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

Investors Business Daily

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

Structure Therapeutics vs. Viking Therapeutics: Which Weight-Loss Drug Stock Wins?

With weight-loss drugs gaining traction, which biopharma stock wins?

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug

Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease.

Investors Business Daily

5 Breakout Biotech Stocks Leading the Russell 2000 Higher

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review

The Dow Jones and S&P 500 rose modestly on the stock market for the week, right around all-time high levels.

Investors Business Daily

3 'Strong Buy' Growth Stocks to Scoop Up Now

High-growth stocks, such as cybersecurity name Zscaler, could be part of your equity portfolio in 2024 - if you're the type of investor who can successfully stomach massive drawdowns in share prices and valuations.

inkl

Read news from The Economist, FT, and more,
with one subscription

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Feisty Rivals Take On Eli Lilly, Novo Nordisk On Weight Loss

Eli Lilly's Mounjaro and Novo Nordisk's Ozempic and Wegovy are headliners in the expected boom in GLP-1 weight-loss drugs. But investors are making even more money on tangential players.

Investors Business Daily

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

5 Russell 2000 Stocks Outperforming the 'Magnificent Seven' in 2024

The "Magnificent Seven" have lost some momentum in 2024, just as small-caps are starting to come on strong. Here's a closer look at five Russell 2000 stocks that are crushing the performance of their mega-cap peers so far this year.

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Up 283% YTD, Is It Too Late to Buy Viking Therapeutics Stock?

Shares of Viking Therapeutics have been on an absolute tear in 2024, as the biotech stock gears up to enter the weight-loss drug market.

Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review

Stock Market Rally At Highs After Big Earnings, Inflation Data: Weekly Review

The stock market is right at record highs amid big earnings movers and economic data that didn't spook bond markets.

Investors Business Daily

Stock Market Today: Stocks End Mixed After Disappointing Economic Data

Stock Market Today: Stocks End Mixed After Disappointing Economic Data

The main indexes made muted moves Tuesday as investors took data that showed a big drop in durable goods and consumer confidence.

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

Viking Therapeutics Catapults 121% As Weight-Loss Drug Beats Out Lilly's Zepbound

A weight-loss drug from Viking topped Lilly's Zepbound in a midstage study Tuesday. Viking stock more than doubled, while Lilly shares fell.

Investors Business Daily

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug

Viking Therapeutics moved up its timeline for an Eli Lilly-rivaling obesity treatment on Thursday, leading VKTX stock to a record high.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Top 1% Biotech Viking Yo-Yos, But Hits A Record, On NASH Enthusiasm

Viking unveiled promising test results Tuesday for a liver disease drug, and VKTX stock hit a record high after initially yo-yoing.

Investors Business Daily

Viking Rockets 69% After Dropping This Scorcher In The Obesity Treatment Battle

Viking said Tuesday recipients of its potential obesity treatment lost up to 18 pounds, and VKTX stock launched to a five-year high.

People

Todd Rosenbluth

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

SP Global Market Intelligence

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play